Scholar Rock Holding Corp（以下简称“公司”）已经做好全面准备，一旦获得美国食品药品监督管理局（FDA）的批准，其药物Apitegromab即刻启动在美国市场的上市进程。这一关键节点锁定在2026年9月30日的《处方药使用者付费法案》（PDUFA）目标日期。
公司上下正厉兵秣马，为这一刻的到来铺平道路。从生产供应链的搭建，到商业化团队的组建，每一个环节都已就绪，只待监管机构的绿灯亮起。届时，Apitegromab将迅速投放市场，惠及广大患者。
这一战略部署彰显了公司对产品获批的坚定信心，也体现了其对市场需求的敏锐把握。随着PDUFA日期的临近，一场精心筹备的市场登陆战即将拉开帷幕。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.